Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.54M | 1.34M | 1.14M | 1.05M | 1.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -186.40K | -- | -- | -- | -- |
| Total Operating Expenses | 6.13M | 3.77M | 1.86M | 1.92M | 2.52M |
| Operating Income | -6.13M | -3.77M | -1.86M | -1.92M | -2.52M |
| Income Before Tax | -6.36M | -2.40M | -771.90K | -2.05M | -2.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.36 | -2.40 | -0.77 | -2.05 | -2.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.36M | -2.40M | -771.90K | -2.05M | -2.64M |
| EBIT | -6.13M | -3.77M | -1.86M | -1.92M | -2.52M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.94 | -0.37 | -0.17 | -0.50 | -0.68 |
| Normalized Basic EPS | -0.59 | -0.23 | -0.11 | -0.31 | -0.43 |
| EPS Diluted | -0.95 | -0.37 | -0.18 | -0.51 | -0.69 |
| Normalized Diluted EPS | -0.59 | -0.23 | -0.11 | -0.31 | -0.43 |
| Average Basic Shares Outstanding | 24.76M | 22.14M | 19.57M | 17.25M | 16.54M |
| Average Diluted Shares Outstanding | 25.24M | 22.62M | 20.04M | 17.25M | 16.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |